Clinical Research Directory
Browse clinical research sites, groups, and studies.
Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Summary
This correlative study aims to understand the pharmacodynamic effects and clonal dynamics in response to epcoritamab by obtaining and analyzing lymph node, bone marrow, and blood samples from subjects enrolled in GCT3013-03 trial sponsored by Genmab at NIH. Samples will be collected before and at multiple time points during treatment with epcoritamab. National Heart, Lung, and Blood Institute (NHLBI) investigators are experienced in testing samples treated with bsAb2,3 including epcoritamab in an ongoing pre-clinical collaboration with Genmab. Addressing the objectives of this correlative study will advance the science and clinical application of epcoritamab specifically as well as T-cell engaging bsAb in general as an emerging class of immunotherapy for cancer. The study is enrolling by invitation only.
Official title: Correlative Study of Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome
Key Details
Gender
All
Age Range
18 Years - 100 Years
Study Type
INTERVENTIONAL
Enrollment
5
Start Date
2025-07-18
Completion Date
2027-07-01
Last Updated
2026-02-17
Healthy Volunteers
No
Interventions
epcoritamab
Samples from subjects receiving epcoritamab on another clinical trial GCT3013-03 will be collected.
Locations (1)
National Institutes of Health Clinical Center
Bethesda, Maryland, United States